NewsRSS2 days ago
A tribute was published honoring Timothy Chan, a young man with Duchenne muscular dystrophy who recently passed away from a respiratory illness. The article celebrates how he inspired others through his approach to life, leadership, and compassion. Duchenne muscular dystrophy is a serious genetic condition that weakens muscles over time, and respiratory complications are a common concern for people with this disease.
WHY IT MATTERSThis story highlights the real-world impact of Duchenne muscular dystrophy and the importance of respiratory monitoring and care, which is critical for patients with this progressive condition.
NewsRSS2 days ago
A person living with Duchenne muscular dystrophy (DMD) attended a performance of Les Misérables and reflected on how the musical's themes of second chances and perseverance mirror their own life journey with this progressive muscle disease. The article connects the emotional arc of the musical to personal experiences of living with a rare genetic condition. This is a personal perspective piece rather than medical news.
WHY IT MATTERSFor people with DMD, reading personal narratives from others living with the same condition can provide emotional support and help them feel less alone in their disease journey.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for Fabry disease patients is currently closed and not accepting new applications. Fabry disease is a rare genetic condition where the body can't break down certain fatty substances, causing problems in the heart, kidneys, and nerves. If you need help paying for Fabry disease treatment, you'll need to check back later or explore other assistance programs.
WHY IT MATTERSIf you have Fabry disease and were counting on PAN Foundation's copay assistance or medication support, you'll need to find alternative financial resources immediately since this program is not currently accepting applications.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for phenylketonuria (PKU) — a rare genetic condition where the body can't break down a protein called phenylalanine — is currently closed. This program normally helps patients pay for treatment costs. The fund status changed on April 20, 2026.
WHY IT MATTERSIf you have PKU and were relying on PAN Foundation assistance to afford your medical care or special diet, you need to find alternative financial resources immediately since this program is no longer accepting applications.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for Gaucher disease patients is currently closed and not accepting new applications. Gaucher disease is a genetic condition where the body can't break down certain fatty substances, causing organ damage. The PAN Foundation helps patients pay for medications and treatment costs when they can't afford them otherwise.
WHY IT MATTERSIf you have Gaucher disease and need help paying for your treatment, you'll need to find alternative financial assistance programs since this major funding source is temporarily unavailable.
NewsUNITERARE4 days ago
The PAN Foundation's financial assistance program for hereditary angioedema (HAE) is currently closed and not accepting new applications. Hereditary angioedema is a rare genetic condition that causes sudden swelling in the face, throat, hands, feet, and digestive system. Patients who need help paying for HAE treatment should check back at the foundation's website or contact them directly to learn when the program might reopen.
WHY IT MATTERSIf you have hereditary angioedema and struggle to afford medications or treatment, this closed fund means you'll need to explore alternative financial assistance programs or payment plans with your healthcare provider right now.
Clinical trialCLINICALTRIALS4 days ago
Williams syndrome is a rare genetic condition that affects about 1 in every 8,000 to 12,000 people. It happens when a person is missing a small section of DNA on chromosome 7, which includes the gene that makes elastin (a protein that helps blood vessels stretch). This causes distinctive facial features and heart and blood vessel problems. Researchers are now recruiting 1,099 people with Williams syndrome or a related heart condition called supravalvular aortic stenosis to donate DNA and tissue samples to help scientists better understand these conditions.
WHY IT MATTERSThis actively recruiting biobank offers Williams syndrome and SVAS patients a direct way to contribute DNA and tissue samples to NHLBI-sponsored research that could accelerate understanding of the genetic causes and lead to new treatments.
NewsUNITERAREApr 3
The PAN Foundation's financial assistance program for phenylketonuria (PKU) — a rare genetic condition that affects how the body processes a protein called phenylalanine — is currently closed and not accepting new applications. The program previously offered up to $12,000 per year to help patients pay for treatment costs. The fund status changed on April 2, 2026.
WHY IT MATTERSIf you have PKU and were relying on this $12,000 annual assistance to afford your special diet or medications, you'll need to find alternative financial support resources immediately.
Clinical trialCLINICALTRIALSApr 1
Researchers are looking for 88 people with Fragile X Syndrome or Creatine Transporter Deficiency to test a new imaging technology that can see how the brain works. Both of these are genetic conditions that affect how the brain develops and cause intellectual disability. This study might help doctors better understand and diagnose these conditions in the future.
WHY IT MATTERSThis trial is recruiting patients with two of the most common X-linked intellectual disability disorders and may provide a new diagnostic tool that could improve how these conditions are identified and monitored.
ResearchPUBMEDMar 26
Scientists studied how different mutations in the CHD4 gene affect the heart and blood vessels in patients with rare diseases. CHD4 is a protein that helps control how genes are turned on and off in cells. By using computer analysis, researchers found that mutations in different parts of this protein cause different types of heart and vessel problems, which could help doctors better understand and classify these genetic conditions.
WHY IT MATTERSThis research provides a framework for doctors to predict how specific CHD4 mutations will affect individual patients' hearts and blood vessels, potentially improving diagnosis and treatment planning for rare conditions like Sifrim-Hitz-Weiss syndrome and moyamoya angiopathy.
Clinical trialCLINICALTRIALSMar 26
Researchers at the National Heart, Lung, and Blood Institute are looking for 1,000 people to join a study about heart and blood vessel diseases that run in families. They want to collect information and blood samples from people who have these genetic diseases, their relatives, and healthy volunteers to better understand how genes affect the heart and blood vessels. This study is open to anyone age 2 and older who may have a genetic condition affecting their heart or blood vessels.
WHY IT MATTERSThis is a large-scale discovery study actively recruiting now that could help identify new genetic causes of inherited heart and vascular diseases, potentially leading to earlier diagnosis and treatment options for affected families.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new genetic tool called RNA-Seq to help diagnose rare diseases in children and adults whose current genetic tests came back negative. This tool looks at how genes are turned on and off in cells, which can reveal problems that standard DNA testing misses. The study will first test the tool in healthy people and those with known genetic conditions, then use it to try to diagnose patients with undiagnosed rare diseases.
WHY IT MATTERSIf you have a child or family member with symptoms of a rare kidney or genetic disease but genetic testing hasn't found answers, this trial could offer a new diagnostic pathway that standard tests have missed.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a new drug called S-606001 to see if it can help adults with late-onset Pompe disease when added to their current enzyme replacement therapy (ERT) treatment. Pompe disease is a rare genetic condition where the body can't break down a type of sugar, causing muscle weakness over time. This study will check if the new drug is safe and if it helps patients feel better or move more easily. The trial is currently looking for 45 adult participants to join.
WHY IT MATTERSThis trial is actively recruiting adults with late-onset Pompe disease who are already on enzyme replacement therapy — eligible participants may be able to access an investigational add-on treatment that could potentially improve their muscle function.